Evaluation of CUL3 Gene Expression Changes in Iranian Population with Colorectal Cancer and Polyps

Subject Areas : Journal of Animal Biology

Zahra Taheri ¹ , Shiva Irani ² , Hamid Asadzadeh Aghdaei ³ , Mohammad Hossein Modarressi ⁴ , Zahra Noormohammadi ⁵

1 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
2 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
3 - Basic and Molecular Epidemiology of Gastroenterology Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 - Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

Received: 2019-09-11 Accepted : 2020-02-03 Published : 2020-02-20

Keywords: Colon, Colorectal cancer, CUL3, Polyp, Rectum,

Abstract :

The bowel or colorectal cancer (CRC) is one of the most common fatal malignancies caused by environmental and genetic factors. The phenomenal growth in the number of people with CRC worldwide, especially in Iran highlights the importance of research on CRC.The current study focused on molecular pathways involved in the carcinogenesis of colorectal cancer to identify a new diagnostic and therapeutic biomarker for CRC.Colorectal cancer is the consequence of dysplasia in the initial intestinal appendages also known as polyps which are different and unknown in terms of morphology, molecular mechanisms, and the ability to affect intestinal carcinogenesis. In this cross-sectional study, 208 colorectal tissue biopsy specimens, including 34 tumor tissue, , 60 precancerous lesions with  adjacent tissue, as well as 20 normal tissue specimens were collected. CUL3 gene expression was evaluated using real-time PCR method. No significant difference was observed in mRNA expression level of CUL3 between polyp tissues and their normal adjacent samples (p = 0.35).Our results showed a statistically significant difference in CUL3 expression neither between tumor tissues and their adjacent normal samples (p = 0.89) nor among tumor and polyp groups (p = 0.48).CUL3 could play a critical role in regulating carcinogenesis and progression of CRC through stimulating proteasomal degradation of various tumor suppressors or oncogenes. Studies on CUL3-affected substrates in colorectal cancer are of significant importance.

References:

1. Bailey C.E., Hu C.Y., You Y.N., Bednarski B.K., Rodriguez-Bigas M.A., Skibber J.M. 2015. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surgery, 150(1): 17-22.

2. Bazensky I., Shoobridge-Moran C., Yoder L.H. 2007. Colorectal cancer: an overview of the epidemiology, risk factors symptoms, and screening guidelines. Medsurg Nursing, 16(1): 46.

3. Center M.M., Jemal A., Smith R.A., Ward E. 2009. Worldwide variations in colorectal cancer. CA: a Cancer Journal for Clinicians, 59(6): 366-378.

4. Coppedè F, Lopomo A, Spisni R, Migliore L,2014. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World Journal of Gastroenterology: 20(4): 943.

5. Cullinan S.B., Gordan J.D., Jin J., Harper J.W., Diehl J.A. 2004. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Molecular and Cellular Biology, 24(19): 8477-8486.

6. Dorr C., Janik C., Weg M., Been R.A., Bader J., Kang R. 2015. Transposon mutagenesis screen identifies potential lung cancer drivers and CUL3 as a tumor suppressor. Molecular Cancer Research, 13(8): 1238-1247.

7. Edwards B.K., Ward E., Kohler B.A., Eheman C., Zauber A.G., Anderson R.N. 2010. Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer, 116(3): 544-573.

8. Grau L., Luque-Garcia J.L., González-Peramato P., Theodorescu D., Palou J., Fernandez-Gomez J.M. 2013. A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness. PloS one, 8(1): e53328.

9. Haagenson K.K., Tait L., Wang J., Shekhar M.P., Polin L., Chen W. 2012. Cullin-3 protein expression levels correlate with breast cancer progression. Cancer Biology and Therapy,13(11):1042-1046.

10. Huo X., Li S., Shi T., Suo A., Ruan Z., Guo H. 2015. Cullin3 promotes breast cancer cells metastasis and epithelial-mesenchymal transition by targeting BRMS1 for degradation. Oncotarget, 6(39): 41959.

11. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. 2011. Global cancer statistics. CA: a Cancer Journal for Clinicians, 61(2): 69-90.

12. Jemal A., Center M.M., DeSantis C., Ward E.M. 2010. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology and Prevention Biomarkers, 19(8):1893-1907.

13. Lao V.V., Grady W.M. 2011. Epigenetics and colorectal cancer. Nature reviews Gastroenterology and Hepatology, 8(12): 686.

14. Lee D.F., Kuo H.P., Liu M., Chou C.K., Xia W., Du Y. 2009. KEAP1 E3 ligase-mediated downregulation of NF-κB signaling by targeting IKKβ. Molecular Cell, 36(1):131-140.

15. Martinez V.D., Vucic E.A., Thu K.L., Pikor L.A., Lam S., Lam W.L. 2015. Disruption of KEAP1/CUL3/RBX1 E3‐ubiquitin ligase complex components by multiple genetic mechanisms: association with poor prognosis in head and neck cancer. Head and Neck, 37(5):727-734.

16. Montazer Haghighi M., Vahedi M., Mohebbi S.R., Pourhoseingholi M.A., Fatemi SR, Zali M.R. 2010. Evaluation of 4-year survival in familial and non familial colorectal cancer. Journal of Islamic Azad Univesity-Tehran Medical Branch, 20(1): 40-44.

17. Mustafa M., Menon J., Muniandy R., Illzam E., Shah M., Sharifa A. 2016. Colorectal cancer: pathogenesis, management and prevention. IOSR Journal of Dentistary Medical Sciences, 15: 94-100.

18. Parker S.L., Tong T., Bolden S., Wingo PA,1997. Cancer statistics, 1997. CA: A Cancer Journal for Clinicians, 47(1): 5-27.

19. Petroski M.D., Deshaies R.J. 2005. Function and regulation of cullin–RING ubiquitin ligases. Nature Reviews Molecular Cell Bbiology, 6(1): 9.

20. Riihimäki M., Hemminki A., Sundquist J., Hemminki K. 2016. Patterns of metastasis in colon and rectal cancer. Scientific Reports, 6: 29765.

21. Safaee A., Fatemi Seyed R., Ashtari S., Vahedi M., Moghimi-Dehkordi B., Zali R. 2012. Four years incidence rate of colorectal cancer in Iran: a survey of national cancer registry data-implications for screening. Asian Pacific Journal of Cancer Prevention, 13(6): 2695-2698.

22. Santero M., Lee D., 2007. Colon polyp symptoms, diagnosis and treatment. MedicineNet.Com.

23. Taguchi K., Motohashi H., Yamamoto M. 2011. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution. Genes to Cells, 16(2): 123-140.

24. Triantafillidis J.K., Vagianos C., Malgarinos G. 2015. Colonoscopy in colorectal cancer screening: Current aspects. Indian Journal of Surgical Oncology, 6(3): 237-250.

25. Wang J., Zhu Z.H., Yang H.B., Zhang Y., Zhao X.N., Zhang M. 2016. Cullin 3 targets methionine adenosyltransferase IIα for ubiquitylation‐mediated degradation and regulates colorectal cancer cell proliferation. The FEBS Journal, 283(13): 2390-2402.

26. Yuan W.C., Lee Y.R., Huang S.F., Lin Y.M., Chen T.Y., Chung H.C. 2011. A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell, 20(2): 214-228.